Peptides are short amino acid chains increasingly sold for unproven longevity, recovery, and weight loss uses, and these compounds are exactly what the panel will judge. Most of its eight new members run businesses that sell them.
When the FDA published eight names on its new peptide advisory panel on Monday, it also published the conflict: most of the appointees run businesses that sell the very compounds the panel will advise the agency on.
The Pharmacy Compounding Advisory Committee is a body that recommends, but does not write, the rules that govern which raw ingredients compounding pharmacies, the custom-mix drug shops that prepare medicines for individual patients, may legally use. On July 23 and 24 it will hold its first meeting under the new roster. Eight new members were published Monday, joining the existing committee. RAPS has previously documented that FDA was weighing whether to add roughly a dozen peptides to the bulk drug compounding list, the policy stakes that this roster will influence.
Peptides are short chains of amino acids, the building blocks of proteins. A few are FDA-approved drugs, including insulin and a growing class of metabolic and weight-loss injections. Many more are sold through compounding pharmacies and wellness clinics for unproven uses: BPC-157 for healing injuries, TB-500 for muscle recovery, MOTS-c for exercise mimicry, Semax and Epitalon for longevity and "anti-aging." The compounds are increasingly advertised directly to consumers online, where the line between pharmaceutical and supplement marketing has grown thin.
STAT reported Monday that a majority of the eight new panelists run businesses that promote or prescribe peptide products. That makes the roster a test of whether the agency that regulates the marketplace is taking advice from a stakeholder group inside it.
The clearest expression sits in the Harshbarger family. One of the new panelists is Tennessee state senator and pharmacist Bobby Harshbarger. His mother, Representative Diana Harshbarger, a Republican also trained as a pharmacist, has publicly urged FDA to ease its regulation of peptides. Putting a member of a family with an explicit lobbying record on the panel that handles the very question that family has lobbied on is a textbook case, though not the only one.
Paul Knoepfler, a University of California, Davis cell biologist and STAT contributor, raised the conflict question in advance. In a spring op-ed, he predicted that Health and Human Services Secretary Robert F. Kennedy Jr. would shape the committee in ways friendly to "popular but unproven peptides." Monday's roster appears consistent with that prediction, according to STAT, which cites Knoepfler flagging that several new panelists sell unproven offerings including stem cells and peptides. Knoepfler's prediction is an expert view, not a settled fact, and his criticism depends on what each panelist discloses in their meeting paperwork.
The FDA's roster page lists the new members but does not detail their financial holdings. Conflict disclosures are typically posted with meeting materials closer to the July meeting.
The agenda for the July 23 to 24 meeting tells readers what the conflict will be applied to. Day one covers BPC-157, an experimental compound pitched for ulcerative colitis and injury recovery; KPV, an anti-inflammatory fragment of the hormone alpha-MSH; TB-500, a fragment of thymosin-beta-4 marketed for muscle and tissue repair; and MOTS-c, a mitochondrial peptide sold as an "exercise mimetic." Day two covers Emideltide/DSIP, a delta sleep-inducing peptide; Semax, a Russian-developed nootropic; and Epitalon, the tetrapeptide Vladimir Khavinson's longevity research is built on. None of these are FDA-approved drugs; all are available today through compounding pharmacies and gray-market sellers. A peptide-industry agenda tracker independently lays out the same day-by-day list, corroborating the FDA calendar.
Whether the panel votes to allow them on the 503A Bulks List, the list of raw substances compounders may use to prepare customized medicines, is the concrete policy lever. Adding a peptide to the list effectively gives compounding pharmacies a legal pathway to make it; leaving it off preserves FDA's current position that these compounds should not be compounded at scale. The committee recommends; the agency follows or ignores its advice.
The next signals to watch are narrow. The FDA's meeting-background materials and disclosed conflicts of interest, expected roughly a week before July 23, will say which panelists have stepped aside from specific votes. The committee's vote on each peptide, day by day, will say whether the roster change matters in practice. And for any consumer reading this who has seen an ad for a peptide treatment or had one prescribed: the regulatory question is live, the meeting is less than four weeks away, and the public dockets are open.